Bridge Biotherapeutics Gears Up to Revolutionize the Biotech Sector at 2023 BIO International Convention

Join Bridge Biotherapeutics Inc. (KQ288330) at the 2023 BIO International Convention in Boston, Massachusetts on Tuesday, June 6, as Director of Business Development Pavel Printsev reveals the company’s exciting clinical-stage assets in a captivating presentation. Bridge Biotherapeutics is a South Korean clinical-stage biotech company pioneering the development of novel drugs for cancer, fibrosis, and inflammation. Discover their latest findings and get a glimpse into what the future of these promising therapies could look like at this one-of-a-kind event.

This year, the company took a major step forward with its acquisition of a diagnostics company boasting a unique biosensing technology. In the upcoming presentation, they will provide a detailed overview of the technology and its expected commercial applications. Get ready to be amazed by the potential of this pioneering biosensing technology.

This year at BIO International, we excitedly invite you to join us in-person to learn more about our groundbreaking research into oncology and pulmonology, as well as the progress of our clinical assets and new business ventures. Last year’s event was just the beginning – come see what strides we’ve made and what’s in store for our future!

About Bridge Biotherapeutics

Bridge Biotherapeutics Inc., a clinical-stage biotech company with headquarters in both the Republic of Korea and the U.S., is pushing the envelope of novel therapeutics. Their focus is on diseases with high unmet needs, such as ulcerative colitis, fibrotic diseases, and cancers. They are leading the way with the groundbreaking BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, and BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis. Moreover, two other cutting-edge treatments are in the works: BBT-176 and BBT-207, targeted cancer therapies for non-small cell lung cancer (NSCLC) with EGFR C797S mutations.

Leave a Comment